Travere Therapeutics to Present at Upcoming Investor Conferences
November 04, 2024 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in...
Travere Therapeutics Reports Third Quarter 2024 Financial Results
October 31, 2024 07:00 ET
|
Travere Therapeutics, Inc.
FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN Type C meeting scheduled with FDA to discuss...
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
October 26, 2024 07:01 ET
|
Travere Therapeutics, Inc.
Travere presents data on FILSPARI (sparsentan) in IgAN and FSGS at ASN Kidney Week 2024.
Travere Therapeutics to Report Third Quarter 2024 Financial Results
October 21, 2024 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2024 financial results on Thursday, October 31, 2024, before the...
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
October 17, 2024 07:01 ET
|
Travere Therapeutics, Inc.
Travere Therapeutics and CSL Vifor announce swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA nephropathy.
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
October 14, 2024 16:30 ET
|
Travere Therapeutics, Inc.
Travere Therapeutics will present 11 abstracts, including one late-breaking abstract, at the upcoming ASN Kidney Week 2024 in San Diego.
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
September 26, 2024 16:01 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2024 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on September 10, 2024, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
September 10, 2024 16:01 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present at the 2024 Cantor Global Healthcare Conference on...
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
September 05, 2024 17:34 ET
|
Travere Therapeutics, Inc.
Travere Therapeutics announced that the U.S. FDA has granted full approval to FILSPARI® (sparsentan) to treat IgA nephropathy.